Nutrients. 2019 May 6;11(5). pii: E1016. doi: 10.3390/nu11051016.
Cesareo R1, Falchetti A2, Attanasio R3, Tabacco G4, Naciu AM5, Palermo A6.
- Calcidiol category listing has
21 items along with related searches
- Calcifediol (25(OH)D3) may be 4 X better than Vitamin D for fortification – Aug 2018
- Is HyD (25(OH)D) a better form of vitamin D for some animals and maybe humans with liver problems
- Calcidiol may be 5X more effective than Vitamin D3 – June 2012
- Oral calcidiol is a good form of vitamin D supplementation – Aug 2017
- Weekly dosing of vitamin D is far better than single large dose (chronic liver, children) – March 2018
- Fatty liver disease in children nicely treated by combination of Vitamin D and Omega-3 – RCT Dec 2016
- Vitamin D is sequestered in Fat: total body, adipose, and liver – Dec 2018
- Liver stores 4 months of vitamin D, 48 months of Vit. A, and 60 months of Vit. B-12
- Poorly functioning livers do not process vitamin D (Calcidiol is needed) – Sept 2014
- Non-alcoholic Fatty Liver Disease (4 in 10 seniors) and Vitamin D
- Calcidiol = 25-hydroxyvitamin D3 = 25(OH)D = Calcifediol (Wikipedia)
- Calcidiol is semi-activated Vitamin D
- Semi-activation is accomplished by enzymes: CYP2A1 in liver and/or CYP2R1 in tissue
- Calcidiol is also available as a drug (oral or injection), an herb, and from eggs and meat
- Wonder if Calcidiol can also be inhaled or applied topically
Getting Vitamin D into your body has the following chart
- Nanoemulsion Vitamin D may be a substantially better form
Hypovitaminosis D is becoming a notable health problem worldwide. A consensus exists among several different medical societies as to the need for adequate levels of vitamin D for bone and general health. The correct method by which to restore normal vitamin D levels is still a matter of debate. Although cholecalciferol remains the most commonly distributed form of vitamin D supplementation worldwide, several drugs with vitamin D activity are available for clinical use, and making the correct selection for the individual patient may be challenging. In this narrative review, we aim to contribute to the current knowledge base on the possible and appropriate use of calcifediol-the 25-alpha-hydroxylated metabolite-in relation to
- its chemical characteristics,
- its biological properties, and
- its pathophysiological aspects.
Furthermore, we examine the trials that have aimed to evaluate the effect of calcifediol on the restoration of normal vitamin D levels.
- Calcifediol is more soluble than cholecalciferol in organic solvents, due to its high polarity.
- Good intestinal absorption and
- high affinity for the vitamin-D-binding protein positively affect the bioavailability of calcifediol compared with cholecalciferol.
- orally administered calcifediol shows a much shorter half-life than oral cholecalciferol.
Most findings suggest that oral calcifediol is about
- three- to five-fold more powerful than oral cholecalciferol, and that it
- has a higher rate of intestinal absorption.
Accordingly, calcifediol can be particularly useful in treating diseases associated with decreased intestinal absorption, as well as obesity (given its lower trapping in the adipose tissue) and potentially neurological diseases treated with drugs that interfere with the hepatic cytochrome P-450 enzyme system, resulting in decreased synthesis of calcifediol. Up to now, there has not been enough clinical evidence for its use in the context of osteoporosis treatment.
Data from the literature are in accord in recommending vitamin D supplementation for all subjects at risk of vitamin D deficiency (Table 2), and the determination of vitamin D deficiency is cost-effective. 25(OH)D values of <20 ng/mL indicate a deficiency, but the requirement of supplementation is still controversial for values between 20 and 30 ng/mL . The majority of the data on vitamin D supplementation in relation to human health almost exclusively involve cholecalciferol in registered clinical trials on anti-fracture drugs in subjects with reduced bone mass; the data highlight skeletal-related endpoints. All these trials have administered cholecalciferol supplementation, although sometimes with different dosages. Consequently, at the moment, robust, evidence-based data that unequivocally demonstrate the effects of the vitamin D hydroxylated metabolite on skeletal health are not available.
Table 2. Categories of patients that should be screened for vitamin D deficiency
- Osteoporosis (particularly if bone-active drugs are to be used)
- Older adults with a history of falls
- Older adults with a history of non-traumatic fractures
- Pregnant and lactating women
- Obese children and adults
- People with insufficient sun exposure
- Malabsorption syndromes (congenital or acquired) and bariatric surgery
- Chronic kidney disease
- Hepatic failure
- Cystic fibrosis
- People taking drugs that interfere with vitamin D metabolism
- (antiseizure medications, glucocorticoids, AIDS medications, antifungals, cholestyramine)
- Granulomatous disorders and some lymphomas
In general, in subjects with hypovitaminosis D, oral calcifediol supplementation is more powerful for increasing serum 25(OH)D concentrations than cholecalciferol. In particular, the calculated relative potency of calcifediol versus cholecalciferol varied between 1.7 and 8, depending on the doses, different pharmacokinetics, and basal 25(OH)D serum levels . A formula has been proposed for calculating the expected increase in circulating 25(OH)D levels when vitamin D is supplemented, which considers age, the baseline 25(OH)D status, and body weight . With this approach, much higher doses of vitamin D3 would be required to realize the same increase in serum 25(OH)D concentration as that observed with calcifediol . In patients affected by hypovitaminosis D without reduced bone mass, calcifediol can be taken instead of cholecalciferol, because it is better able to increase circulating 25(OH)D levels without the need to use micro- or macro-boli.
To summarize, compared with cholecalciferol, calcifediol
- is absorbed the best,
- has a different volume of distribution,
- is independent from hepatic 25-hydroxylase, and
- produces a more rapid increase in circulating levels of 25(OH)D [6,62].
In particular, calcifediol is a more polar and soluble metabolite that may display smaller volumes of distribution, and less trapping by the adipose tissue . Consequently, these aspects affect both its intestinal absorption and circulating DBP transport, as well as the whole body distribution of its orally administered metabolite, displaying a much shorter half-life (approximately 10-13 days) than the parental cholecalciferol [16,58,108-110]. The use of calcifediol might be more cost-effective in obese patients and in those with malabsorption syndromes. Its use may be beneficial in patients taking drugs that interfere with the hepatic cytochrome P-450 enzyme system, particularly corticosteroid drugs or anticonvulsants. Thus, at least in these specific conditions, calcifediol can be used as an alternative to cholecalciferol  and, assuming the above-described higher pharmacologic activity of oral calcifediol relative to oral cholecalciferol , the cost per IU of calcifediol could be about six time lower than that of cholecalciferol (according to the market prices in Italy in 2019) [112,113], although such a direct comparison between the costs of these different molecules cannot lead to an accurate and adequate proposal.
Quesada-Gomez JM and colleague suggested "oral calcifediol as a valid and favorable alternative for the prevention or treatment of osteoporosis" . Instead, we are strongly convinced that further studies are needed to investigate the efficacy and safety of calcifediol in the clinical setting of bone